Open-label riluzole in fragile X syndrome - Erickson, Craig A.; Weng, Ning; Weiler, Ivan Jeanne; Greenough, William T.; Stigler, Kimberly A.; Wink, Logan K.; McDougle, Christopher J. (Brain research, 2011)
Keywords: administration & dosage; adults; adverse effects; animal models; biomarkers; brain; Child; Child Development Disorders, Pervasive; Child Development Disorders, Pervasive - drug therapy; Child Development Disorders, Pervasive - physiopathology; Child Development Disorders, Pervasive - psychology; children; drug therapy; drugs; ERK; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Antagonists - administration & dosage; Excitatory Amino Acid Antagonists - adverse effects; Fragile X Syndrome; Fragile X Syndrome - drug therapy; Fragile X Syndrome - metabolism; Fragile X Syndrome - physiopathology; glutamic acid; Humans; liver function; Male; metabolism; Neurology; Neuroprotective Agents; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - adverse effects; pathophysiology; people; physiopathology; Pilot Projects; Prospective Studies; psychology; Riluzole; Riluzole - administration & dosage; Riluzole - adverse effects; Young Adult; Riluzole; Fragile X syndrome; ERK